Monte Rosa Therapeutics, Inc. (GLUE)
| Market Cap | 897.50M +44.7% |
| Revenue (ttm) | 28.73M -83.9% |
| Net Income | -161.12M |
| EPS | -1.75 |
| Shares Out | 85.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,094,588 |
| Open | 10.29 |
| Previous Close | 10.30 |
| Day's Range | 10.14 - 10.63 |
| 52-Week Range | 8.94 - 25.77 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 26.88 (+155.51%) |
| Est. Earnings | Nov 5, 2026 |
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL... [Read more]
Financial Performance
In 2025, Monte Rosa Therapeutics's revenue was $123.67 million, an increase of 63.54% compared to the previous year's $75.62 million. Losses were -$38.63 million, -46.87% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for GLUE stock is "Strong Buy." The 12-month stock price target is $26.88, which is an increase of 155.51% from the latest price.
News
Monte Rosa Therapeutics assumed with a Buy at UBS
UBS assumed coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and price target of $19, up from $17. The firm believes the company’s MRT-8102, a first-in-class oral NEK7…
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann...
Monte Rosa Therapeutics Transcript: Study result
The GFORCE-1 phase I study of MRT-8102 in subjects with elevated cardiovascular risk demonstrated robust NEK7 degradation, normalization of key pathogenic drivers (DAMPs, IL-1 beta, CRP), and a favorable safety profile across all dose levels. These results support broad development in ASCVD, gout, and HS, with phase II studies planned using biomarker and genetic enrichment strategies.
Monte Rosa Therapeutics Press release: Study result
Monte Rosa Therapeutics issued a press release on October 1, 2026, disclosing material business information to investors.
Monte Rosa Therapeutics Slides: Study result
Monte Rosa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on October 1, 2026.
Monte Rosa announces data from GFORCE-1, plans for Phase 2 program of MRT-8102
Monte Rosa Therapeutics (GLUE) announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by th...
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases, normaliz...
Monte Rosa Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Monte Rosa Therapeutics (GLUE) with a Buy rating and $25 price target The company is undervalued at a $565M enterprise value given its two wholly-owned…
Monte Rosa Therapeutics to present results of MRT-8102 GFORCE-1 Phase 1 study
The company states: “Monte Rosa Therapeutics (GLUE) announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will…
Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk
BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an...
Monte Rosa Therapeutics Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is advancing a pipeline of molecular glue degraders, with three clinical assets and a focus on NEK7 for ASCVD, gout, and HS. Strategic partnerships, notably with Novartis for MRT-6160, support rapid development in autoimmune indications. Cash runway extends into 2029, enabling progress across all key programs.
Monte Rosa Therapeutics to receive $50M milestone payment from Novartis
Monte Rosa Therapeutics (GLUE) announced that its collaborator Novartis (NVS) has initiated a Phase 2 clinical study for the VAV1-directed MGD MRT-6160 in people living with Sjogren’s disease. This st...
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
Phase 2 study to be conducted in participants with Sjögren's disease Novartis conducting study under global exclusive development and commercialization license agreement with Monte Rosa Monte Rosa to ...
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today an...
Monte Rosa Therapeutics doses first patient in MODeFIRe-1 trial
Monte Rosa Therapeutics (GLUE) announced that the first patient has been dosed in MODeFIRe-1, a Phase 2 study evaluating MRT-2359 in combination with apalutamide, a second-generation androgen receptor...
Monte Rosa Therapeutics Announces First Patient Dosed in MODeFIRe-1, a Phase 2 Study of MRT-2359 in Combination with Apalutamide in Patients with AR Mutation-Positive Metastatic Castration-Resistant Prostate Cancer
Monte Rosa FPD in MODeFIRe-1, a P2 Study of MRT-2359 in Combo w/ Apalutamide in Patients w/ AR Mutation-Positive Metastatic Castration-Resistant Cancer
Monte Rosa Therapeutics price target lowered to $28 from $35 at Guggenheim
Guggenheim lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $28 from $35 and keeps a Buy rating on the shares after updating the firm’s model to reflect…
Monte Rosa Therapeutics reports Q2 revenue $8.97M, consensus $12.88M
“We’re tremendously proud of our progress to date in 2026, defined by strong execution across our clinical-stage portfolio, with two Phase 2 trials activated and additional trials expected across our…
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
Completed enrollment and dosing for GFORCE-1 study of MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk; readout anticipated in H2 2026 Company expects to initiate multiple MRT-8102...
Monte Rosa Therapeutics Quarterly report: Q2 2026
Monte Rosa Therapeutics has published its Q2 2026 quarterly earnings report on August 6, 2026.
Monte Rosa Therapeutics Earnings release: Q2 2026
Monte Rosa Therapeutics released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Monte Rosa Therapeutics Slides: Corporate presentation
Monte Rosa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 6, 2026.
Monte Rosa Therapeutics price target lowered to $27 from $37 at Wedbush
Wedbush analyst Robert Driscoll lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $27 from $37 and keeps an Outperform rating on the shares. The firm notes competitor…
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback
Monte Rosa Therapeutics (GLUE) is trading lower after Novo Nordisk’s (NVO) ZEUS trial failed to show a cardiovascular benefit for IL 6 inhibition, a readout that dampens sentiment around inflammation…
Monte Rosa Therapeutics price target lowered at Jefferies after Novo trial miss
Jefferies lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $25 from $40 and keeps a Buy rating on the shares after Novo Nordisk’s (NVO) ZEUS study of…